IRCT20210608051515N1尚未招募3 期
Efficacy of Cannabidiol (CBD) in Patients with Treatment-Resistant Frontal Lobe Epilepsy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Drug resistant frontal lobe epilepsy diagnosis (Insufficient or no response to two or more of anti epileptic agents)
排除标准
- •Consumption of any derivative of marijuana or cannabis plant in recent month
- •Any of the aforementioned medications in regimen: Clobazam, DesMethyl Clobazam, Eslicarbazepin, Topiramate, Zonisamide, Warfarin
研究者
相似试验
招募中
3 期
Evaluation of the effect of cannabidiol in the treatment of dystoniaDystoniaIRCT20211019052811N1Mashhad University of Medical Sciences60
尚未招募
1 期
Efficacy and Safety of Low-dose Cannabidiol for treatment of sleep disturbancesACTRN12623000802606PharmaCann Pty Ltd80
进行中（未招募）
1 期
Adjunctive cannabidiol therapy in patients with CDKL5 deficiency disorder. Interventional drug study on efficacy and safety with focus on seizure effectspatients with CDKL5MedDRA version: 20.0Level: PTClassification code 10015039Term: Epilepsy congenitalSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-001959-13-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE15
招募中
不适用
Cannabidiol enhancement of exposure therapy in patients with phobias.Phobic anxiety disorders, fobische angststoornissenNL-OMON28305trecht University72
进行中（未招募）
不适用
Does adding cannabidiol (a component of cannabis) enhance the treatment of phobias where patients are confronted with their fears (exposure treatment).EUCTR2014-004094-17-NLniversiteit Utrecht